Advanced Cell Technology (OTC BB: ACTC) another Site for Dry AMD Clinical Trial
Bascom Palmer will be a new ACT P1/2 site for the clinical trial(s)
using Human Embryonic Stem Cell-Derived RPE Cells for dry AMD
Bascom Palmer Eye Institute in Miami, Fla., has received institutional review board (IRB) approval as a site for the OTC BB: ACTC’s P1/2 clinical trial for dry age-related macular degeneration (dry AMD), using human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells.
- The P1/2 trial is a prospective, open-label study designed to determine the safety and tolerability of the hESC-derived RPE cells following sub-retinal transplantation into patients with dry AMD. The trial will ultimately enroll 12 patients, with cohorts of 3 patients each in an ascending dosage format.
The Bottom Line: Good choice … to advance trials … Bascom Palmer Eye Institute is ranked as the #1 ophthalmology hospital in the country and has a particularly strong reputation in the area of macular degeneration.
Related Posts
Categories: ACTC.OB, Advanced Cell Technology, Dry AMD
